PUBLIC COMPANY
save$UTHRUNITED THERAPEUTICS Corp
$UTHR587.88-0.56%Silver Spring, MD, USupdated 7h ago
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; and Manchester, New Hampshire.
community read0 votes
pipeline
6
marketed
4
phase 3
2
catalysts ytd
6
approvals ytd
1
recalls ytd
0
Pipeline(6)
pipeline depth6 products
2Phase 34Marketed
Marketed
Remodulin
Pulmonary Arterial Hypertension
MarketedTyvaso DPI
Pulmonary Arterial Hypertension
Marketeddinutuximab
Neuroblastoma
Marketedtreprostinil diolamine ER
Pulmonary Arterial Hypertension
Phase 3ralinepag XR
Pulmonary Arterial Hypertension
Prostacyclin receptor
Phase 3treprostinil
Idiopathic Pulmonary Fibrosis
Prostacyclin receptor
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (2)
Active trials
- phase3An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
- phase3Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
- phase2Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
- phase3Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
- phase3Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- N/AStudy on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)
- —DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- phase3A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
🐶 Hiring Signal
News
- Spyre’s arthritis misses; Ideaya ends eye cancer trialPlus news about United Therapeutics. Spyre Therapeutics reports additional trial failures: The biotech said its long-acting anti-TL1A drug, codenamed SPY072, did not meet the primary endpoints in t…endpoints · 12d ago
- Sanofi's new German site; radioisotope deals from Northstar and TelixPlus more from Baxter and United Therapeutics. Sanofi starts construction of an insulin factory: Sanofi has broken ground on a new 36,000-square-meter manufacturing facility at its site in Frankfur…endpoints · 25d ago
- Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slumpPlus news about United Therapeutics, Liquidia, Sanofi, Pharming, Skyhook Bio and Altay Therapeutics. Ultragenyx Pharmaceutical sells second PRV this month: The commercial-stage rare disease drugmak…endpoints · 1mo ago
- STAT+: FDA adcomm members’ ties to industry under scrutinyNew research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…stat · 1mo ago
- Roivant, the 'inveterate drug hunters', enters commercial era with LisrayaCEO Matt Gline is juggling Roivant Sciences' first solo drug launch and several maturing programs as the hub-and-spoke company sets its sights on a massive turning point into commercial viability.biospace · 1mo ago
- Varda raises $251M to leverage gravity in space for drug productionCapitalizing on space’s microgravity, the United Therapeutics–partnered Varda Space Industries aims to make medicines with better bioavailability and stability than Earth-produced molecules.biospace · 1mo ago
- United Therapeutics' legal victory; BMS' Camzyos approved for kidsPlus, news about United Therapeutics, MindRank, Novo, Atara Biotherapeutics, Pierre Fabre, Monte Rosa Therapeutics, Bristol Myers Squibb’s Camzyos and Skopos Bio. Nektar Therapeutics' shares drop 2…endpoints · 1mo ago
- Roivant's pulmonary hypertension drug shines with ‘blowout’ Phase 2 dataMosliciguat, being developed by the Roivant Sciences subsidiary Pulmovant, 'significantly exceeded expectations' in reducing pulmonary vascular resistance, according to analysts, and is progressing…biospace · 2mo ago
- FDA extends review of Capricor cell therapy; Pain drug startup to go publicThe agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.biopharma_dive · 2mo ago
- Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion proteinTolerance Bio has vaulted into the clinic by agreeing to pay NeoImmuneTech up to $260 million for rights to a fusion protein in certain thymus-related indications in the Americas and Europe.fiercebiotech · 3mo ago
Data sources
last refreshed 58m ago
Found something off?
comments(0)
5-min edit window · permanent after that